Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of apremilast versus placebo in moderate to severe plaque psoriasis
2010-019992-30Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis and psoriasis comparing Apremilast 30 mg BID with Placebo (2 arms). Primary endpoint: PASI-75 response at Week 16. Started Nov 2010; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2010-019992-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019992-30.